The aim of this observational study is to compare the use of an extended release paracetamol formulation with standard paracetamol in a cohort of Australian concessional patients with osteoarthritis (OA), to assess differences in prescribing patterns and patient compliance.
This retrospective analysis of physician prescribing data (long-term concessional cohort from the Medicare Australia PBS claims dataset for the time period 2008-2011 (4 years) will compare the use of extended release paracetamol (Panadol Osteo) with standard paracetamol 500mg in a cohort of Australian concessional patients with OA, to assess differences in prescribing patterns and patient compliance.
Study Type
OBSERVATIONAL
Paracetamol 665 mg tablet
Paracetamol 500 mg tablet
Relative number of prescriptions of an extended release paracetamol formulation and a standard release paracetamol formulation.
Number of episodes of treatment for OA with the extended release formulation and the standard release formulatins will be counted.
Time frame: January 2009 to December 2010
Relative treatment compliance with an extended release paracetamol formulation and a standard release paracetamol formulation
Interval between the repeat doses of extended release paracetamol formulation and the standard release paracetamol formulation.
Time frame: January 2009 to December 2010
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.